Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb/III trial to evaluate thymosin beta 4 (RGN 259) in patients with moderate to severe dry-eye syndrome

Trial Profile

Phase IIb/III trial to evaluate thymosin beta 4 (RGN 259) in patients with moderate to severe dry-eye syndrome

Status: Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Aug 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Timbetasin (Primary)
  • Indications Dry eyes
  • Focus Therapeutic Use
  • Sponsors G-treeBNT
  • Most Recent Events

    • 06 Aug 2015 Status changed from planning to not yet recruiting according to RegeneRx media release.
    • 17 Jul 2015 According to RegeneRx media release, company has recently received an IND for this trial.
    • 17 Feb 2015 According to a RegenRx media release, G-treeBNT filed an IND for this phase IIb/III trial in South Korea in Dec 2014, it is expected to be initiated in 2015, with results in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top